These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39147616)

  • 1. Effect of CYP3A5 Gene Polymorphisms on Tacrolimus Blood Concentrations and Adverse Events in Allogeneic Hematopoietic Stem Cell Transplant Patients.
    Jiang J; Luan J
    Transplant Proc; 2024 Sep; 56(7):1678-1682. PubMed ID: 39147616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of CYP3A5 gene polymorphism on tacrolimus concentration and adverse events in patients undergoing allogeneic hematopoietic stem cell transplantation].
    Chen X; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Jiang EL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):828-833. PubMed ID: 34788922
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of
    Suetsugu K; Mori Y; Yamamoto N; Shigematsu T; Miyamoto T; Egashira N; Akashi K; Masuda S
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
    Yamashita T; Fujishima N; Miura M; Niioka T; Abumiya M; Shinohara Y; Ubukawa K; Nara M; Fujishima M; Kameoka Y; Tagawa H; Hirokawa M; Takahashi N
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):111-8. PubMed ID: 27217047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
    Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients.
    Zhu J; Patel T; Miller JA; Torrice CD; Aggarwal M; Sketch MR; Alexander MD; Armistead PM; Coghill JM; Grgic T; Jamieson KJ; Ptachcinski JR; Riches ML; Serody JS; Schmitz JL; Shaw JR; Shea TC; Suzuki O; Vincent BG; Wood WA; Rao KV; Wiltshire T; Weimer ET; Crona DJ
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
    Yildirim E; Şahin G; Kaltuş Z; Çolak E
    Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
    Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
    Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Khaled SK; Palmer JM; Herzog J; Stiller T; Tsai NC; Senitzer D; Liu X; Thomas SH; Shayani S; Weitzel J; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):268-276. PubMed ID: 26325438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients.
    Htun YY; Swe HK; Saw TM
    Transplant Proc; 2018 May; 50(4):1034-1040. PubMed ID: 29731062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
    Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
    J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
    Roy JN; Barama A; Poirier C; Vinet B; Roger M
    Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
    Wang L; Li N; Wang MX; Lu SC
    Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients.
    Uno T; Wada K; Matsuda S; Terada Y; Oita A; Kawase A; Takada M
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):665-673. PubMed ID: 29691732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
    Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
    Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
    Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
    Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients.
    Xing J; Zhang X; Fan J; Shen B; Men T; Wang J
    Eur J Clin Pharmacol; 2015 Feb; 71(2):191-8. PubMed ID: 25487141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.